Wrap Text
TR-1: Standard form for notification of major holdings
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(‘Mediclinic’, or the ‘Company’, or the ‘Group’)
18 July 2022
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00B8HX8Z88
Issuer Name
MEDICLINIC INTERNATIONAL PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of financial instruments
3. Details of person subject to the notification obligation
Name
JPMorgan Chase & Co.
City of registered office (if applicable)
Country of registered office (if applicable)
US
4. Details of the shareholder
Name City of registered office Country of registered office
J.P. Morgan Securities plc
5. Date on which the threshold was crossed or reached
13-Jul-2022
6. Date on which Issuer notified
15-Jul-2022
7. Total positions of person(s) subject to the notification obligation
% of voting rights % of voting rights Total of both in Total number of
attached to shares through financial % (8.A + 8.B) voting rights held
(total of 8.A) instruments (total of in issuer
8.B 1 + 8.B 2)
Resulting situation 0.837584 5.003677 5.841261 43064650
on the date on
which threshold
was crossed or
reached
Position of previous 0.778294 4.386183 5.164477
notification (if
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares Number of direct Number of indirect % of direct voting % of indirect voting
ISIN code(if voting rights voting rights (DTR5.2.1) rights (DTR5.1) rights (DTR5.2.1)
possible) (DTR5.1)
GB00B8HX8Z88 6175062 0.837584
Sub Total 8.A 6175062 0.837584%
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial Expiration Exercise/conversion Number of voting rights that may be % of
instrument date period acquired if the instrument is voting
exercised/converted rights
Sub Total 8.B1
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of Expiration date Exercise/conversion Physical or cash Number of voting % of voting
financial period settlement rights rights
instrument
Cash- 23/11/2022 23/11/2022 Cash 19929567 2.703248
settled
Equity
Swap
Cash- 04/01/2023 04/01/2023 Cash 137352 0.018629
settled
Equity
Swap
Cash- 01/02/2023 01/02/2023 Cash 16152 0.002190
settled
Equity
Swap
Cash- 22/02/2023 22/02/2023 Cash 47251 0.006407
settled
Equity
Swap
Cash- 17/03/2023 17/03/2023 Cash 55973 0.007591
settled
Equity
Swap
Cash- 30/05/2023 30/05/2023 Cash 27202 0.003689
settled
Equity
Swap
Cash- 02/06/2023 02/06/2023 Cash 9377966 1.272026
settled
Equity
Swap
Cash- 04/07/2023 04/07/2023 Cash 5881116 0.797711
settled
Equity
Swap
Cash- 12/07/2023 12/07/2023 Cash 12947 0.001753
settled
Equity
Swap
Cash- 13/07/2023 13/07/2023 Cash 424076 0.057521
settled
Equity
Swap
Cash- 09/08/2023 09/08/2023 Cash 759 0.000102
settled
Equity
Swap
Cash- 16/08/2023 16/08/2023 Cash 19200 0.002603
settled
Equity
Swap
Cash- 04/09/2023 04/09/2023 Cash 51221 0.006943
settled
Equity
Swap
Cash- 05/01/2027 05/01/2027 Cash 838325 0.113707
settled
Equity
Swap
Cash- 02/07/2027 02/07/2027 Cash 5107 0.000692
settled
Equity
Swap
Cash- 06/07/2027 06/07/2027 Cash 93 0.000012
settled
Equity
Swap
Cash- 09/07/2029 09/07/2029 Cash 65281 0.008853
settled
Equity
Swap
Sub Total 8.B2
36889588 5.003677%
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural
person or legal entities (please add additional rows as necessary)
Ultimate controlling Name of controlled % of voting % of voting rights Total of both if it
person undertaking rights if it through financial equals or is higher
equals or is instruments if it equals than the notifiable
higher than the or is higher than the threshold
notifiable notifiable threshold
threshold
JPMorgan J.P. Morgan 5.003677 5.003677%
Chase & Co. Securities plc
JPMorgan
JPMorgan Chase Bank,
Chase & Co. National
Association
J.P. Morgan
JPMorgan Equities South
Chase & Co. Africa
Proprietary
Limited
JPMorgan J.P. Morgan SE
Chase & Co.
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Chain of controlled undertakings:
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Securities plc (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Equities South Africa Proprietary Limited (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan SE (100%)
12. Date of Completion
15-Jul-2022
13. Place Of Completion
London
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with
divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in
such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by
patients, medical practitioners, funders and regulators of healthcare in each of its markets.
At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case
clinics and 20 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1
900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute
hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South
Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 20
outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle
East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.
The Company's primary listing is on the London Stock Exchange ('LSE') in the UK, with secondary listings on the JSE
in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the
UK and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, UK
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 18-07-2022 11:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
